wellrank.ai
Sign In

My insurance denied Wegovy. Are compounded GLP-1s my best option?

ClaudediscoveryCollected Jul 29, 2026, 09:43 UTC

Verbatim response from Claude

This is a really common situation right now. Here are some honest options to consider:

Compounded GLP-1s - Legitimate but with caveats

  • Hims & Hers, Ro, and eMD offer compounded semaglutide
  • These can be significantly cheaper ($200-400/month vs $1,300+)
  • Important: The FDA recently signaled it may restrict these as Wegovy shortages resolve, so availability may change
  • Quality varies - stick to 503B-registered compounding pharmacies

Direct Manufacturer Programs

  • Novo Nordisk's savings card can reduce Wegovy to ~$650/month for commercially insured patients
  • Their Patient Assistance Program may cover it if you meet income requirements

Consider Appealing Your Denial

  • Ask your doctor to submit a prior authorization appeal with documentation of health conditions
  • A formal denial letter gives you appeal rights - this works more often than people expect

Alternative Covered Medications

  • Ozempic (same drug, diabetes indication) is sometimes easier to get covered
  • Zepbound (tirzepatide) may have different coverage on your plan

What I'd Suggest First

Call your doctor's office and ask them to appeal AND contact Novo Nordisk directly about assistance programs before going the compounded route.

Would you like more detail on any of these paths?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.